Combining RSPH9 founder mutation screening and next-generation sequencing analysis is efficient for primary ciliary dyskinesia diagnosis in Saudi patients.

MLA

Mabrouk, Imed, et al. “Combining RSPH9 Founder Mutation Screening and Next-Generation Sequencing Analysis Is Efficient for Primary Ciliary Dyskinesia Diagnosis in Saudi Patients.” Journal of Human Genetics, vol. 67, no. 7, July 2022, pp. 381–86. EBSCOhost, https://doi.org/10.1038/s10038-021-01006-9.

APA

Mabrouk, I., Al-Harthi, N., Mani, R., Montantin, G., Tissier, S., Lagha, R., Ben Abdallah, F., Hassan, M. M., Alhomrani, M., Gaber, A., Alsanie, W. F., Ouali, H., Jambi, F. A., Almaghamsi, T. M., Alqarni, N. A., Alfarsi, N. A., Kashgari, K., Al-Zahrani, H. J., Al-Shamary, Z. A., … Legendre, M. (2022). Combining RSPH9 founder mutation screening and next-generation sequencing analysis is efficient for primary ciliary dyskinesia diagnosis in Saudi patients. Journal of Human Genetics, 67(7), 381–386. https://doi.org/10.1038/s10038-021-01006-9

Chicago

Mabrouk, Imed, Nawal Al-Harthi, Rahma Mani, Guy Montantin, Sylvie Tissier, Rihab Lagha, Fethi Ben Abdallah, et al. 2022. “Combining RSPH9 Founder Mutation Screening and Next-Generation Sequencing Analysis Is Efficient for Primary Ciliary Dyskinesia Diagnosis in Saudi Patients.” Journal of Human Genetics 67 (7): 381–86. doi:10.1038/s10038-021-01006-9.